Titanium Media App reported on August 10 that Watson Bio disclosed its semi-annual report on the evening of August 10. The company’s semi-annual revenue in 2022 was 2.348 billion yuan, a year-on-year increase of 73.96%; net profit attributable to the parent was 421 million yuan, a year-on-year increase. 31.90%; basic earnings per share was 0.26 yuan. In the first half of the year, the subsidiary Yuxi Watson 13-valent pneumonia conjugate vaccine received batches of 3.7315 million doses, an increase of 39.68% over the same period of the previous year. In the first half of the year, some product production lines of Yuxi Watson underwent equipment renovation due to the rectification of the WHO-PQ project and other reasons. In addition, the adjustment of the production plan of related products resulted in a large decrease in the number of batches issued for some vaccine products. After the rectification is completed, the production of related products and batch issuance will resume gradually.
- 2022-08-10 Watson Bio: Net profit in the first half of the year was 421 million yuan, a year-on-year increase of 31.9%
- 2020-12-07 Watson Bio: The proposal to transfer the equity of Shanghai Zerun will not be submitted to the general meeting of shareholders for deliberation
- 2020-12-06 After the phone call was bombarded, the supervisor quickly issued an inquiry letter. Watson Bio urgently stopped the transfer and fell nearly 18% at the opening
This article is reprinted from: https://readhub.cn/topic/8imXAyt5j6S
This site is for inclusion only, and the copyright belongs to the original author.